EndoShunt — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

EndoShunt is a pre-revenue medical device startup targeting the critical unmet need for rapid hemorrhage control in trauma surgery. Its core technology is a guidewire-free, length-adjustable, temporary shunt designed to be deployed in under 30 seconds to stop bleeding from major abdominal vascular injuries. The company has developed functional prototypes validated in benchtop and in vivo studies, has a defined regulatory pathway for FDA 510(k) clearance as a Class II device, and is seeking $2M in funding to achieve clearance and initiate a targeted pilot launch.

TraumaCardiovascular

Technology Platform

Minimally invasive, temporary endovascular shunt with guidewire-free deployment, length adjustability, and rapid removal for targeted hemorrhage control.

Opportunities

The device addresses a critical, high-mortality unmet need in trauma surgery with a potentially practice-changing solution.

Successful adoption in the $366M abdominal trauma beachhead market could enable expansion into adjacent, larger hemorrhage control markets (e.g., thoracic, pelvic) and establish a new standard of care for temporary vascular control.

Risk Factors

Key risks include failure to obtain FDA 510(k) clearance, challenges in driving adoption in protocol-driven trauma centers, establishing favorable reimbursement, and the execution risk of scaling from prototype to commercial launch with limited capital.

Competition from alternative hemorrhage control techniques also poses a threat.

Competitive Landscape

EndoShunt competes indirectly with a range of hemorrhage control methods, including manual surgical clamping, resuscitative endovascular balloon occlusion of the aorta (REBOA), permanent stent grafts, and topical hemostatic agents. Its primary differentiation is offering rapid, temporary, and targeted control specifically designed for the trauma setting, unlike permanent implants or less targeted balloon occlusion.

More companies in Drug Delivery & Formulation →More companies in United States →